Export 4 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q [R] S T U V W X Y Z   [Show ALL]
Ragab, Dina, Melissa Laird, Darragh Duffy, Armanda Casrouge, Rasha Mamdouh, Amal Abass, Dina El Shenawy, Abdelhadi M. Shebl, Wagdi F. Elkashef, Khaled R. Zalata et al. "CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients." CYTOKINE 63 (2013): 105-112. Abstract
Razavi, H., I. Waked, C. Sarrazin, R. P. Myers, R. Idilman, F. Calinas, W. Vogel, M. C. Mendes Correa, C. Hézode, P. Lázaro et al. "The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm." Journal of viral hepatitis 21 Suppl 1 (2014): 34-59. Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

Raziky, Maissa El, Waleed Fouad Fathalah, Wafaa Ahmed El-akel, Ahmed Salama, Gamal Esmat, Mahassen Mabrouk, Rabab Mamoun Salama, and Hany Mahmoud Khatab. "The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study." HEPATITIS MONTHLY 13 (2013). Abstract
Raziky, M. E., W. El-Akel, M. A. Soliman, S. El Kafrawy, M. Abdel-Hamid, M. K. Mostafa, M. Sjogren, T. Strickland, and G. Esmat. "Sustained virological responders to interferon therapy for chronic hepatitis C Genotype 4: is there a possibility of relapse?" LIVER INTERNATIONAL 26 (2006): 4. Abstract